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Abstract
Background: Trials in Africa indicate that medical adult male circumcision (MAMC) reduces the risk of HIV by 60%. MAMC
may avert 2 to 8 million HIV infections over 20 years in sub-Saharan Africa and cost less than treating those who would have
been infected. This paper estimates the financial and human resources required to roll out MAMC and the net savings due
to reduced infections.
Methods: We developed a model which included costing, demography and HIV epidemiology. We used it to investigate 14
countries in sub-Saharan Africa where the prevalence of male circumcision was lower than 80% and HIV prevalence among
adults was higher than 5%, in addition to Uganda and the Nyanza province in Kenya. We assumed that the roll-out would
take 5 years and lead to an MC prevalence among adult males of 85%. We also assumed that surgery would be done as it
was in the trials. We calculated public program cost, number of full-time circumcisers and net costs or savings when
adjusting for averted HIV treatments. Costs were in USD, discounted to 2007. 95% percentile intervals (95% PI) were
estimated by Monte Carlo simulations.
Results: In the first 5 years the number of circumcisers needed was 2 282 (95% PI:2 018 to 2 959), or 0.24 (95% PI:0.21 to 0.31)
per 10 000 adults. In years 6–10, the number of circumcisers needed fell to 513 (95% PI: 452 to 664). The estimated 5-year cost
of rolling outMAMCinthepublicsector was$919 million (95%PI:726 to1 245).Thecumulativenetcostover thefirst10 years
was $672 million (95% PI: 437 to 1 021) and over 20 years there were net savings of $2.3 billion (95% PI: 1.4 to 3.4).
Conclusion: A rapid roll-out of MAMC in sub-Saharan Africa requires substantial funding and a high number of circumcisers
for the first five years. These investments are justified by MAMC’s substantial health benefits and the savings accrued by
averting future HIV infections. Lower ongoing costs and continued care savings suggest long-term sustainability.
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Introduction
Observational studies have repeatedly shown that male
circumcision (MC) offers substantial protection against HIV
infection [1]. Three randomised controlled trials (RCTs) recently
confirmed these findings, with consistent estimates of effectiveness.
In 2005, the first RCT of medical adult MC (MAMC), conducted
in Orange Farm, South Africa, found a risk reduction between
study arms of 60% (95% CI: 32 to 76) [2]. Combined with the two
other RCTs conducted in Kenya and Uganda, the overall risk
reduction was 58% (95% CI: 43 to 69%) [3–5].
The encouraging results of the Orange Farm trial prompted
wide interest in Africa towards MC as an HIV prevention strategy.
Currently about a third of the African male population is
circumcised but the practice is less common in southern and East
Africa, where the HIV epidemic is especially severe. The
circumcision of adult males was shown to be more effective and
cost-effective than other general population HIV prevention
strategies [6]. Making MAMC a public health priority has been
endorsed by international agencies such as WHO and UNAIDS
[7]. In 2006, supported by UNAIDS and WHO, most sub-
Saharan African countries with low MC prevalence and high HIV
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2679prevalence started preparing for the implementation of MAMC.
Zambia decided not to wait for the results of the Ugandan and
Kenyan trials, integrating MAMC in its national plan against HIV
in the beginning of 2006.
The acceptability of MAMC appears to be high. Before the clinical
trials were completed, studies were conducted in nine African
countries with a high HIV prevalence and a low MC prevalence.
Most uncircumcised males were willing to become circumcised
(median 65%; range 29 to 87%) and most women were willing to
have their sons circumcised (median 81%; range 70 to 90%) [8].
The results of the Orange Farm trial suggest that MAMC could
have a substantial impact on health, with favourable economic
implications. An epidemic model estimated that full coverage of
MAMC in African countries where the majority of males are
uncircumcised would avert 2 to 8 million HIV infections in the
next 10 years [9] while a cost-effectiveness model applied to
Gauteng Province, South Africa, suggested that performing 1 000
MAMCs in South Africa would avert 189 to 428 HIV infections
and would save $1.3 to $3.6 million over 20 years [6].
Given the favourable evidence for the impact and feasibility of
MAMC and the WHO-UNAIDS recommendations to expand
access to safe male circumcision services [7], funding will likely
become available for the widespread implementation of MAMC in
the near future. It is thus crucial to evaluate the economic
requirements and consequences for rolling out MAMC in Africa.
The objectives of the present study were to estimate the human and
financial resources needed for a rapid roll-out of MAMC and the net
costs or savings when taking into account averted costs of HIV
medical care. We focused on 14 countries with existing male
circumcision prevalence lower than 80% and HIV prevalence among
adults higher than 5%, since these settings have been shown tobe best
for MAMC to produce a large reduction in HIV with favourable
economic outcomes. Wealsoincluded two sites whererecent MAMC
trials were conducted: the Nyanza province of Kenya (the area of
Kenya meeting the inclusion criteria) and Uganda.
Methods
We developed a cost model of MAMC integrated with a
demographic and HIV epidemic model. The technical details of
the model are provided in Supporting Information S1, which is
available as a spreadsheet upon request from the corresponding
author. We ran the model for each of the 16 locations (15
countries and one province) and summed them up to obtain
aggregate results. We included Botswana, Burundi, Central
African Republic, Kenya’s Nyanza province, Lesotho, Liberia,
Malawi, Mozambique, Namibia, Rwanda, South Africa, Swazi-
land, Tanzania, Uganda, Zambia and Zimbabwe. In 2007, these
countries had a combined total adult population (aged 15 to 49) of
96 million, or 29% (96/331) of the corresponding age group for all
42 sub-Saharan countries. The number of HIV-positive adults was
estimated to be 14.6 million (59.8% of the infected people in sub-
Saharan Africa, 14.6/24.3) [9]. The number (%) of uncircumcised
adult males was estimated to be 30.5 million (56.4%, 30.5/54.1).
South Africa provided the largest proportion of all uncircumcised
adults in the sample (26.1%) (Table 1).
Table 1. Setting-specific model inputs (for calendar year: 2007) and cost predictions on rolling out medicalised adult male
circumcision using the public cost model.
Setting Model input data Model predictions
Population aged
15 to 49 years
(millions)
Prevalence of
MC before MAMC
intervention
(percent)
Uncircumcised
adults in millions
(% of total)
Adult
prevalence of
HIV (percent)
Number of
circumcisers in
the first 5 years*
Funding required for
MAMC programming
(million US$), total for
first 10 years
Botswana 0.91 25 0.34 (1.1%) 37.3 25 (18 to 37) 25 (17 to 36)
Burundi 3.41 2 1.67 (5.5%) 6.0 146 (107 to 209) 47 (32 to 64)
CAR** 1.81 67 0.3 (1%) 13.5 16 (9 to 25) 5 (3 to 8)
Kenya**** 2.15 10 0.97 (3.2%) 24.0 82 (59 to 117) 30 (21 to 41)
Lesotho 0.86 0 0.43 (1.4%) 28.9 35 (26 to 51) 13 (9 to 17)
Liberia 1.62 70 0.24 (0.8%) 5.9 12 (7 to 19) 4 (2 to 6)
Malawi 5.45 17 2.26 (7.4%) 14.2 190 (142 to 285) 63 (42 to 84)
Mozambique 9.02 56 1.98 (6.5%) 12.2 130 (90 to 196) 45 (29 to 61)
Namibia 0.94 15 0.4 (1.3%) 21.3 31 (22 to 45) 19 (14 to 27)
Rwanda 3.98 10 1.79 (5.9%) 5.1 152 (114 to 225) 51 (36 to 68)
South Africa 24.47 35 7.95 (26.1%) 24.6 549 (401 to 796) 451 (313 to 649)
Swaziland 0.51 50 0.13 (0.4%) 38.8 8 (6 to 12) 5 (3 to 7)
Tanzania 18.09 70 2.71 (8.9%) 8.8 133 (74 to 220) 45 (24 to 70)
Uganda 11.64 25 4.37 (14.3%) 4.1 364 (266 to 528) 127 (87 to 169)
Zambia 4.89 12 2.15 (7.1%) 16.5 182 (134 to 264) 69 (49 to 93)
Zimbabwe 6.26 10 2.82 (9.2%) 24.6 227 (168 to 326) 78 (56 to 105)
Total 96.01 - 30.52 (100%) - 2 282 (2 018 to 2 959) 1 077 (855 to 1 448)
Average - 36 - 15.6 - -
*Assuming scale-up to maximum acceptable coverage over an initial period of 5 years (see text).
**Central African Republic.
****Province of Nyanza.
doi:10.1371/journal.pone.0002679.t001
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individuals matched by gender, age group (child/adult), male
circumcision status and HIV status. HIV-positive individuals could
receive antiretroviral therapy (ART) and died of AIDS or of other
causes (Figure S1). HIV transmission was simulated in a simple,
dynamic, compartmental model, without consideration of strata of
sexual risk behaviour [9]. To this model we added the MAMC
intervention, cost parameters and details on ART.
We assumed that a given number of adults were circumcised
each year, independently of their HIV status, until full coverage
was achieved. We estimated the cost and effect of this intervention
on HIV as a function of time. We assumed that a fixed proportion
of males were already circumcised before becoming adults and
that this was constant over time.
The demographic parameters and the HIV epidemic model
were kept simple in order to allow for the calculation of anticipated
resource needs and program cost with a reduced set of input
parameters. Comparison with earlier models assured a realistic
representation of the key factors related to demography, HIV and
male circumcision status as well as the cost of the intervention.
The full list of input parameters is reported in Table 2 with
numerical values for South Africa. Key country-specific param-
eters except cost are given in Table 1.
Cost models
We assumed that MAMC services were intensive for the first
five years, in order to achieve maximum attainable circumcision
levels, and then dropped to the rate necessary to maintain these
levels. It was assumed that in this ‘‘initial period’’ of five years a
large constant annual number of MAMCs were performed,
sampled randomly among all uncircumcised adult men willing to
be circumcised. The prevalence of MC rose rapidly. When MC
prevalence reached the specified threshold, MAMC acceptance
was saturated and dropped to a lower rate. The proportion of
males becoming adults who refused MAMC determined long-term
MC saturation. Thus, after the initial period, the number of
circumcisions performed annually was reduced to the number of
male children/adolescents entering adulthood, not already
adequately traditionally circumcised and willing to be circumcised.
For this analysis, we assumed that current neonatal and childhood
MC practices did not change. We assumed that the roll-out led to
an increase in the prevalence of MC among adult males to 85% in
all settings. In the sensitivity analysis, we assumed an MC
prevalence increase to 55%, except for the 4 countries with an MC
prevalence greater than this limit: Central African Republic,
Liberia, Mozambique and Tanzania.
Program costs were composed of initial and annual costs. We
explored a public cost scenario assuming the use of government
health infrastructures only and a private cost scenario assuming
reliance on private health care providers only.
In the public cost scenario, initial costs were per circumci-
sion facility (for medical equipment and certification) and for
training circumcisers. Annual costs included the oversight and
promotion of MAMC, the salaries of full-time circumcisers,
surgical staff and counsellors, the direct non-salary cost of each
MAMC (i.e., surgical supplies), facility overhead (i.e., operating
costs) and program overhead.
The number of personnel required was based on the experience
of the authors and expert opinion. In particular, we assumed that
each circumciser could complete 10 circumcisions per day, as
observed in recent clinical trials. For each circumciser, there was
1.0 medical assistant and 0.5 counsellor. These numbers were
based on MC delivery experience in the trial in Orange Farm and
were consistent with a recent study of 4 clinics in Swaziland [10].
The total salary for this 1.5 full-time equivalent was set at 59% of
that of the circumciser, reflecting a salary of approximately 40% of
the circumciser’s, based on the WHO CHOICE health cost
database for the AFRO-E region [11]. This staffing level
accounted for the surgery itself plus time for follow-up, treating
adverse events and counselling.
Unit cost estimates (Table 2) were derived from market data, the
WHO CHOICE health cost database for the AFRO-E region [11],
scientific literature, expert opinion and extrapolation from similarly
structured public health programs. The costs of expendable
supplies, such as drugs, anaesthesia and some instruments were
based on the purchase price of 100 manufactured disposable MC
kits ($11) [12]. The facility overhead costs (i.e., administration,
facility maintenance, utilities) were set at 67% of the direct salary
and supply costs, based on a study of 11 circumcision units in 3
countries [13]. The costs of oversight and promotion (i.e.,
management, communication and monitoring) were set at 26% of
facility-level costs, based on a review of 9 approved ‘‘Round 6’’
proposals to the Global Fund to Fight AIDS, Tuberculosis and
Malaria for HIV prevention programs in sub-Saharan African
countries [14]. We arrived at a total overhead of 110% as the
combined effect of facility and program overheads, i.e.,
(1.6761.26)21. To account for differences in price levels and
salaries among countries, we adjusted most costs per health facility
according to gross domestic product per capita. This resulted in
sharp differences in salaries between the highest income countries
(i.e., South Africa and Botswana) and other countries in this
analysis.Inacomplementaryanalysis,weusedtheWHOCHOICE
AFRO-E regional physiciansalary ($1 236 per month) for the lower
income countries, without gross domestic product per capita
adjustment. For internationally priced items (e.g., drugs), standard
unit costs were used. We did not include the cost of HIV voluntary
counselling and testing, since it is currently funded through other
mechanisms and may not be required by many MC programs.
In the private cost scenario, all facility-level costs were
included in the price per MAMC paid to providers. These
providers were already equipped to perform MAMC and there
were no initial costs. The price of each MAMC covered salaries of
circumcisers, other health staff, counselling, surgical supplies,
follow-up, treatment of adverse events and operating costs. This
per-circumcision price could presumably correspond to a higher
unit cost than in the public scenario, due to differences in private
sector costs (e.g., higher wages) or pricing strategies by providers.
We spoke with informants in various settings, who provided us
with a wide range of currently asked prices, from $25 in Kenya to
$376 (Zambian 15 bed private clinic). In South Africa we obtained
an average price of $72. In a first analysis we assumed that the cost
of MAMC was $72 across all settings. This value was varied from
250% to +50% (36 to 99) in the sensitivity analysis. In addition to
direct provider payments we assumed annual program overhead
costs of 10% to cover the public promotion of MAMC.
To calculate costs and savings from HIV treatment,w e
assumed that 30% of HIV-infected individuals eligible for
antiretroviral treatment were receiving it. The averted cost of
medical treatment for HIV over time was a function of the number
of HIV infections averted each year and the rate of disease
progression, combined with associated medical costs. We assigned
medical costs by stages of disease, based on a study in South Africa
[15], with adjustment by country for local inputs (e.g., salaries)
according to per capita GNP, since WHO CHOICE did not
provide country-level details.
The analysis adopted the perspective of a government health
care payer. In the private cost scenario, the cost of each MAMC
was reimbursed by the government. Since all and only direct
Cost of Male Circumcision
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tives were similar. Program costs were discounted to 2007 at 3%
per year [16]. Costs were expressed in U.S. dollars.
Anticipated resource needs and program costs
We calculated the number of full-time circumcisers
needed based on the productivity of circumcisers (circumcisions
per day) and the duration of the initial period. We calculated two
economic outputs. Program costs needed to roll out MAMC
were calculated as the sum of the resources required to deliver a 5-
year scale-up of MAMC to saturation and the resources required
for the maintenance of MAMC over an additional 15 years, across
all 16 settings. This 5-year period was changed to 7 and 9 years in
the sensitivity analysis. Net costs or savings represented the
costs of MAMC minus the savings due to averted medical care
costs for HIV.
Uncertainty range
The uncertainty of anticipated resource needs and program
costs to input uncertainty was determined using Monte Carlo
Table 2. Key input parameters and numerical values corresponding to the South African scenario, for the year 2007.
Demography Value
Relative
uncertainty
range* (%)
Initial population size of adults in the geographical setting 24 470 000 [9] 0
Crude birth rate 1.8% per year [28] 20
Newborns reaching adulthood (age 18) 88% [29] 20
Life expectancy when becoming adult (without HIV) 47 years [30,31] 20
Boys circumcised before reaching adulthood 35% [32] 10
HIV epidemic model
Initial HIV prevalence among adults at start of intervention 24.6% [33] 20
Ratio of male-to-female and female-to-uncircumcised-male HIV transmission rates, in the absence of MC 1.5 [34,35] 50
Reduction in female-to-male transmission of HIV due to MC 60% [2] 20
HIV medical treatment
Percent of HIV-positive people receiving treatment before becoming eligible for ART 30% (AE) 20
Cost of this treatment (total per patient) $729 US$ (AE) 50
Percent of HIV-positive people eligible for ART who receive ART 30% [36] 50
Life expectancy on ART 10 years [37] 50
Cost of ART for eligible patients (per patient per year) 993 US$ [37] 50
Percent of HIV-positive people eligible for ART who receive non anti retroviral treatment 30% (AE) 50
Cost of this treatment (lifetime total per patient) 2 743 US$ [37] 50
MAMC program parameters
Duration to reach maximum male circumcision prevalence 5 years (AE) 0
Number of circumcisions per day per circumciser 10 (AE) 50
Number of working days per year 230 (AE) 20
Adult males who will remain uncircumcised 15% (AE) 50
Public MAMC program cost
Initial investment per circumcision facility 28 778 US$ (AE) 50
Number of circumcisers per circumcision facility 2 (AE) 50
Initial training per circumciser 8 985 US$ (AE) 50
Salary of each circumciser 2 246 US$ per month [38] 50
Salary of health care workers/counsellors per circumciser 59% of the circumciser [38] 50
Supplies cost per patient circumcised 11 US$ [12] 50
Facility and program overheads (detail in text) 110% of all costs (AE) 50
Private MAMC program cost
Circumcision cost 72 US$ (AE) 50
Annual program overhead cost 10% (AE) 50
Miscellaneous parameters
Discount rate 3% per year [16] 0
The same assumptions were used for other countries and settings, except for the country-specific parameters given in Table 1 and for unit costs adjusted to reflect
differences in gross domestic product per capita (see text).
AE=author’s estimates.
*A range of x% for a parameter of a value v indicates that the range in which this parameter was varied from v(12x) to v(1+x).
doi:10.1371/journal.pone.0002679.t002
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Gaussian distribution (62 standard deviations) to the specified
uncertainty range indicated in Table 2. The output range was
defined as the 2.5th to 97.5th percentile interval (95% PI) among
1 000 repetitions, when all inputs were varied simultaneously.
Results
Number of circumcisers and HIV infections averted
Table 1 shows the number of circumcisers needed for MAMC
roll-out for each individual setting. In the aggregate analysis across
all 16 settings, the number of full-time circumcisers needed for
MAMC roll-out over the initial, intensive 5-year phase was 2 282
(95% PI: 2 018 to 2 959). This represented 0.24 per 10 000 adults
(95% PI: 0.21 to 0.31) (Table 3). Upon reaching the ‘saturation’
coverage level, in years 6 to 10, the required number of
circumcisers dropped to 513 (95% PI: 452 to 664) (Table 3).
Figure 1 presents, for South Africa, the number of full-time
circumcisers needed as a function of time when the initial period
was spread over 5, 7 and 9 years. With a shorter initial period over
which maximum coverage was the goal, the required number of
circumcisers was highest.
Over the first 10 and 20 years of MAMC roll-out, the number
of circumcisions per HIV infection averted was 10.1 (95% PI: 9.0
to 11.2) and 5.6 (95% PI: 5.1 to 6.2), respectively.
Costs using the public scenario
Table 1 shows the program funding needed for MAMC roll-out
for each individual setting using the public scenario. The bulk of
costs and circumcisions was in South Africa (which has the largest
national population), followed by Uganda, Zimbabwe, Zambia
and Malawi (with large populations and low MC prevalence).
The program cost over the first 5 years was $919 million (95%
PI: 726 to 1 245) in the public scenario (Table 4). The annual cost
fell by 83% after year 5, due to lower volume of services. The
program cost over 20 years was $1 347 million (95% PI: 1 070 to
1 784).
The required MAMC program funding over the first 10 years
for the 16 settings varied only slightly, between $ 919, 1 019 and
971 for the initial periods of 5, 7 and 9 years, respectively. The
lower cost for the longer period of 9 years was due in part to a
lower initial investment in circumcision centres and MC training.
Net costs and savings are reported in Table 4. The public
scenario had a net cost over the first 10 years of $672 million (95%
PI: 437 to 1 021). For South Africa this net cost was $265 million
(95% PI: 121 to 471). Over a period of 20 years, there were
substantial net savings of $2.3 billion (95% PI: 1.4 to 3.3). For
South Africa the net savings were $960 million (95% PI: 439 to
1 522). With an MC prevalence increase among adult males to
55% instead of 85%, the cost over a 10-year period was
$483 million (95% PI: 324 to 797) and the savings over a 20-
year period were $1.0 billion (95% PI: 0.6 to 1.7).
Over the first 10 and 20 years of MAMC roll-out, the cost per
HIV infection averted varied from $338 to $168 (Table 4). For
South Africa this latter cost was $255 (95% PI: 172 to 379) over
the first 20 years in the public sector.
When using the AFRO-E regional average salaries for the 14
lowest income settings (leaving South Africa and Botswana at
higher levels), the program cost over 5 years was $1 279 million
(95% PI: 1 074 to 1 657), slightly higher than the upper 95% PI of
the main analysis. The program cost over 20 years was
$1 912 million (95% PI: 1 612 to 2 438), again slightly above
the main analysis upper 95% PI. The net savings over 20 years,
taking into account averted HIV care, were $2 324 million (95%
PI: 1 356 to 3 350). This value is similar to what was obtained in
the main analysis despite a higher program cost, due to higher
averted HIV care costs using the AFRO-E regional salaries.
Costs using the private scenario
With a private cost set at $72 ($79.2 with overhead), the
program cost over 5 years was $1 961 million (95% PI: 1 612 to
2 298) and $3 011 million (95% PI: 2 499 to 3 527) over 20 years.
Net savings at 20 years were $610 million (265 to 1 676). With a
cost per MC of $32 (excluding 10% program overhead), the
program cost over 20 years in the private and public sector was the
same. A net cost over 20 years of $0 was achieved at a private cost
of $87 per AMC (excluding 10% program overhead).
Discussion
This study provides the first estimates of the cost of scaling up
MAMC in sub-Saharan Africa, the number of circumcisers
needed and the likely savings due to averted HIV medical care
costs. After numerous observational studies, three randomised
controlled studies, a modelling study and a cost-effectiveness study,
this analysis provides further evidence supporting the rapid roll-
out of MC in sub-Saharan Africa. Cumulative net costs at 20 years
are negative for the base case and for almost all sensitivity analyses,
indicating that the intervention will save money.
This study has some limitations. On the costing/demand aspect,
the predicted number of circumcisers required depends on the
Table 3. Number of circumcisers required to roll out MC in 16
settings of sub-Saharan Africa, as a function of time.
Number of circumcisers required
Total number (95% PI) / Per 10 000 adult
population (95% PI)
Years 1 to 5 2 282 (2 018–2 959) / 0.24 (0.21 to 0.31)
Years 6 to 10 513 (452 to 664) / 0.053 (0.047 to 0.069)
Years 11 to 20 567 (496 to 730) / 0.059 (0.052 to 0.076)
PI=percentile interval.
doi:10.1371/journal.pone.0002679.t003
Figure 1. Number of circumcisers per 10 000 adults required,
by year, to reach maximum MC level in 5, 7 and 9 years,
respectively, in South Africa.
doi:10.1371/journal.pone.0002679.g001
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base case assumption that a period of 5 years will be sufficient to
circumcise most of the uncircumcised males might be seen as
optimistic. The sensitivity analysis showed that the required number
of circumcisers would be less with a longer start-up phase; however,
the associated costs to scale up MAMC were relatively insensitive to
this duration. Our assumption that a high fraction of uncircumcised
men would accept circumcision may be considered an upper limit,
reflecting the hypothesis that education campaigns promoting
MAMC might even increase demand above levels reported in
acceptability studies. Finally, our assumption about circumciser
productivity is based on recent experience and may turn out to be
conservative as efforts are made to design and evaluate more
efficient surgical methods and ways of deploying staff.
Despite the consistent impacts found in the 3 RCTs, the exact
impact that MAMC will have when scaled up in the field remains
uncertain. For example, impact observations in these trials were all
limited to the first 2 years after surgery. In addition, the indirect
effect of circumcision on preventing mother-to-child transmission
and associated reductions in medical costs were not taken into
account in our model.
The mathematical model used to calculate epidemiological
impact was a simple susceptible-infected compartmental model
[9], which, for example, does not account for heterogeneity in
HIV transmission by age. Our prediction of impact on HIV
infections is similar to that of other HIV epidemic models [6,9].
For example, our estimates of the number of MAMCs required to
avert an HIV infection and program cost per HIV infection
averted are consistent with a prior analysis using slightly different
modelling assumptions [6]. Our impact estimate is higher than one
study [17], with differences due mainly to epidemic severity and
modelling time horizon. This consistency with past work, in
combination with the robustness of our findings in multivariate
sensitivity analysis, suggests that our results are likely to be
reasonable predictions of epidemic impact and associated financial
savings from HIV care averted.
Our analysis cannot be used to estimate precisely the difference
in costs between a private and a public scenario, due to a lack of
firm data on the cost of either scenario, especially with evidence of
wide variation in private pricing. A pragmatic view suggests that
each delivery approach has advantages and disadvantages. The
main advantage of the private provider scenario is that it is
immediately available: subsidies to private sector MAMC facilities
by public or private donors will make this sector quickly
operational. The disadvantage of the private sector approach is
its likely higher long-term cost, the lack of private doctors in many
rural areas threatening geographical equity in access and the
insufficient number of doctors to fully cover the need for MAMC.
The main advantage of the public sector approach is its
potentially lower cost in the longer term and potentially better
geographic equity. The main disadvantage is that the health
system may take time to make MC available on a large scale. The
public system may require infrastructure development and
training of health workers.
Summed over all the countries evaluated, the cost estimates for
rolling out MAMC may appear to be high. We nevertheless think
that this cost is affordable, for several reasons. First, the cost is high
only for a few initial years: once most men have been circumcised,
the cost will be reduced to the circumcision of men becoming
adults (and eventually to newborns). Second, the cost is an
investment which will prevent spending far greater resources in
treating persons with HIV/AIDS in future years. Compared with
our ART costing assumptions, the costs of ART may even increase
if treatment initiation criteria are widened (to earlier stages of
infection/disease) in coming years, due to longer therapy and an
increasing need for more expensive second- and third-line
regimens. Furthermore, spending for MC is modest compared
with overall HIV control efforts: our prediction of annual funding
required for MAMC roll-out for a 10-year period in the public
provider scenario is only one-quarter of the current spending of
the PEPFAR program: $433 million annually in 5 countries of
Southern Africa [18]. The projected funding requirements for
MAMC represent a significant and highly variable proportion of a
country’s total public and private health expenditures, estimated at
0.3%, 1.1%, 2.3% and 6.0% for South Africa, Tanzania,
Zimbabwe and Botswana, respectively [19]. While this has
important implications for planning and budgeting, it does not
reflect on long-term affordability, since MAMC is cost saving.
We calculated that, over the first 5 years, about 1/4 full-time
circumcisers would be required per 10 000 adults. Current general
practitioners may be too few (especially those trained and willing
to perform MC) and too busy to fulfil such a need [20,21].
Furthermore, the training of general practitioners takes time and it
is not reasonable to assume general practitioners will do just MC.
Thus we believe that the training of nurses with an accreditation
system could be a rapid way to increase the capacity of the private
sector. The workforce shortage being the biggest barrier to roll out
of MAMC [22], the involvement of nurses is likely to be a crucial
step for an accelerated roll-out of MC. It will require some
regulation adjustments because in many countries where MC is
not common nurses are not allowed to perform MAMC, even in
places where traditional circumcisers without medical knowledge
and training are tolerated.
One of the main obstacles to the roll-out of MAMC is the
relative technical difficulty of the surgery, which requires precise
Table 4. Funding and net cost of rolling out MC using the
public cost model, pooled across 16 countries/settings of sub-
Saharan Africa.
Public cost model
Funding (million US$) through year 5
Total (95% PI) 919 (726 to 1 245)
Average per year (95% PI) 184 (145 to 249)
Funding (million US$) years 6–10
Total (95% PI) 158 (126 to 204)
Average per year (95% PI) 32 (25 to 41)
Funding (million US$) through year 10
Total (95% PI) 1 077 (855 to 1 448)
Average per year (95% PI) 108 (86 to 145)
Funding (million US$) through year 20
Value (95% PI) 1 347 (1 070 to 1 784)
Average per year (95% PI) 67 (53 to 89)
Cost per HIV infection averted over 10 years 338 (266 to 456)
Cost per HIV infection averted over 20 years 168 (133 to 223)
Cumulative net cost* (95% PI) in million US$
at 10 years
672 (437 to 1 021)
Cumulative net cost* (95% PI) in million US$
at 20 years
22 274 (23 318 to 21 416)
PI=percentile interval.
*Net cost is the program cost minus savings due to averted HIV medical care
(million US$; 95% percentile interval in brackets). Negative value indicates net
savings.
doi:10.1371/journal.pone.0002679.t004
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be greatly facilitated and accelerated by the development of
simplified, bloodless methods [23], which would lighten and
shorten the training required for health workers and decrease
costs. A full review of these bloodless methods and their
acceptability in modern medical practice is therefore an urgent
public health need [24]. In addition, we are exploring the
applicability of ‘‘task specialization’’ team methods with substan-
tially higher productivity per circumciser, similar to those
pioneered for cataract removal surgery in Asia in the 1980s [25–
27]. This approach can also make excellent use of low level health
care workers for the less technical parts of the procedure (e.g.,
patient preparation and wound dressing).
A major consideration in scaling up MAMC is whether to
concentrate on a horizontal or vertical approach. The horizontal
approach is exemplified by the integration of MAMC into routine
clinical practice. It is best represented in this analysis by the private
sector scenario, since many general practitioners are likely to do
MAMC as part of their varied clinical activities. The vertical
approach makes MAMC a stand-alone activity. The public sector
scenario may work with a vertical or horizontal emphasis, or a
mix. The vertical approach offers potential to contribute uniquely
to a rapid scale-up and the horizontal approach offers more
structure for sustainability. We believe that a combination is
preferred and that the optimal scale-up methods will depend on
the health care system settings. We have not distinguished the cost
of the public sector’s horizontal versus vertical approaches, which
will be the subject of future analyses.
The rapid implementation of MC will necessitate more than just
funding. It will require broad involvement from many groups:
national political leaders, activists, teachers, street leaders,
churches and health workers. MAMC roll-out will also require
strong and steady political support. The political involvement of
South Africa will be key, as South Africa represents a high fraction
of the population that could benefit the most and has a leading
political role in the African region. Our hope is that the research
done in the past 20 years regarding the potential of MC to reduce
the spread of HIV will be recognized not merely as scientific
progress, but as the foundation for an effective transition from
knowledge to high-impact practice.
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